We are live on ! Find out more
BIOTW

Biotech Acquisition Company Warrant
BIOTW

Delisted

BIOTW was delisted on the 2nd of February, 2023.

Back to rankings

48 hedge funds and large institutions have $3.83M invested in Biotech Acquisition Company Warrant in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1% more capital invested

Capital invested by funds: $3.8M → $3.83M (+$38.3K)

6% less funds holding

Funds holding: 51 → 48 (-3)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
48
Holders Change
-3
Holders Change %
-5.88%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
4
Closed
4
Calls
$5.82M
Puts
–
Net Calls
+$5.82M
Net Calls Change
+$98K

Top Buyers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
+$2.34K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$395
3
MC
Meteora Capital
Florida
+$196
4
RA
Ramius Advisors
New York
+$59

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$1.36K
2
BCM
Basso Capital Management
Connecticut
-$1K
3
OCAM
Owl Creek Asset Management
New York
-$1K
4
PCM
Prelude Capital Management
New York
-$1K
5
UBS Group
UBS Group
Switzerland
-$960
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$2.05M – – –
BFM
2
Boothbay Fund Management
New York
$611K -$128 -3,339 -5%
LP
3
LMR Partners
United Kingdom
$505K – – –
SCM
4
Segantii Capital Management
Hong Kong
$252K – – –
HIM
5
HGC Investment Management
Ontario, Canada
$78K – – –
PAMP
6
Polar Asset Management Partners
Ontario, Canada
$39.7K – – –
AC
7
Aristeia Capital
Connecticut
$37.4K – – –
RA
8
Ramius Advisors
New York
$36.4K +$59 +1,540 +0.3%
CCP
9
Corbin Capital Partners
New York
$29.7K – – –
QGA
10
Q Global Advisors
Texas
$19K – – –
ACM
11
Atalaya Capital Management
New York
$16.7K – – –
LA
12
Linden Advisors
New York
$15.4K – – –
SCM
13
Shaolin Capital Management
Florida
$13K – – –
TI
14
Telemetry Investments
New York
$10K – – –
SC
15
Sculptor Capital
New York
$9.32K – – –
DKCM
16
Davidson Kempner Capital Management
New York
$9K – – –
TCM
17
Tenor Capital Management
New York
$8.96K – – –
MI
18
MMCAP International
Cayman Islands
$8.95K – – –
AC
19
Antara Capital
New York
$7K – – –
RCM
20
Rivernorth Capital Management
Florida
$6.65K – – –
ACA
21
Arena Capital Advisors
California
$6.39K – – –
CH
22
CVI Holdings
Delaware
$6.39K – – –
PC
23
Periscope Capital
Ontario, Canada
$6.39K – – –
Walleye Capital
24
Walleye Capital
New York
$4.14K – – –
HF
25
HRT Financial
New York
$4K – – –
1
2

BIOTW Hedge Fund Activity: Q4 2022 in Review

48 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q4 2022, worth a combined $3.83M — up 1% from $3.8M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of BIOTW and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was K2 Principal Fund, opening a new position worth an estimated $2.34K. The largest seller was Citadel Advisors, cutting an estimated $1.36K.

  • 48 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q4 2022, down from 51 in Q3 2022.
  • Funds reported $3.83M of Biotech Acquisition Company Warrant stock for Q4 2022, up 1% quarter-over-quarter.
  • 2 funds opened new Biotech Acquisition Company Warrant positions in Q4 2022 and 4 closed out, a net change of -2 holders.
  • The largest Biotech Acquisition Company Warrant buyer in Q4 2022 was K2 Principal Fund, an estimated $2.34K added.
  • The largest Biotech Acquisition Company Warrant seller in Q4 2022 was Citadel Advisors, an estimated $1.36K sold.

Based on aggregated 13F filings for Q4 2022.